DOI:
10.1055/s-00000009
American Journal of Perinatology
LinksClose Window
References
The IMpact Study Group.
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.
Pediatrics 1998;
102 (03) 531-537
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.